Drug added to transplant shows promise for blood cancer patients
NCT ID NCT04384692
Summary
This study is testing whether adding the drug ruxolitinib before, during, and after a stem cell transplant can improve results for people with myelofibrosis, a serious bone marrow cancer. The transplant is currently the only treatment with potential to cure the disease, but it carries a high risk of a dangerous complication where the donor cells attack the patient's body. Researchers hope ruxolitinib will reduce this complication and help patients live longer with better quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.